Diversification of Quinazolinones by Pd-Catalyzed C(sp3)-Acetoxylation
摘要:
The quinazolinone ring has been exploited as a directing group for C(sp(3))-H functionalization for the first time. The proximal C-gamma(sp3)-H bonds have been oxidized by palladium-catalyzed acetoxylation reaction. Various functional groups on the quinazolinone scaffold were tolerated to provide novel quinazolinone derivatives. The use of base was found to be crucial for the mono selective acetoxylations.
The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.
Two-Directional Approach for the Rapid Synthesis of 2,4-Bis-Aminoaryl Pyridine Derivatives
作者:Rémy Morgentin、Bernard Barlaam、Kevin Foote、Lorraine Hassall、Janet Hawkins、Clifford D. Jones、Antoine Le Griffon、Aurelien Peru、Patrick Plé
DOI:10.1080/00397911.2010.520403
日期:2012.1.1
pyridine compounds from a common starting material. The C-4/C-2 approach uses palladium-mediated coupling reactions to sequentially functionalizeC-4 and then C-2. An alternative C-2/C-4 route uses a regioselective SNAr reaction to first substitute at C-2 then subsequently at C-4 by a palladium-mediated reaction. Both approaches have been used successfully to provide a range of 2,4-bis-aminoaryl pyridine
Development of novel 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists
作者:Takashi Mizutani、Tsuyoshi Nagase、Sayaka Ito、Yasuhisa Miyamoto、Takeshi Tanaka、Norihiro Takenaga、Shigeru Tokita、Nagaaki Sato
DOI:10.1016/j.bmcl.2008.10.034
日期:2008.12
Novel 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone derivatives were identified as potent human H(3) receptor inverse agonists. After systematic modification of lead 5a, the potent and selective analog 5r was identified. Elimination of hERG K(+) channel and human alpha(1A)-adrenoceptor activities is the main focus of the present study.
The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I)
wherein A
1
, A
2
,
R
1
, R
2
, R
3
, R
4
, R
5
and R
6
are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as therapeutics.
[EN] NITROGEN CONTAINING HETEROARYL COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROARYLES CONTENANT DE L'AZOTE
申请人:HOFFMANN LA ROCHE
公开号:WO2011154327A1
公开(公告)日:2011-12-15
The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I) wherein A1, A2, (a), R1, R2, R3, R4, R5 and R6 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit PDE10A and can be used as medicaments.